(24/7 MARKET NEWS) – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced, today, that it received Institutional Review Board (IRB) approval to proceed with its Clinical Trial for the treatment of Type 1 Diabetes with its CELZ-201 cell therapy. The FDA previously cleared its Investigational New Drug (IND) application within 30 days from submission.
Creative Medical Technology is at $1.04, up $0.5281 (+155.91%), on 7 million premarket shares.
Its 52-week trading range is $0.33 to $5.145. It’s blown through several resistance levels and trading at its May price levels. If can maintain the strong volume, its setup is favorable for a potential run to challenge the $2 resistance range.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
